Studies with a range of experimental animal and human tumours have demonstrated that lymph node cells or peripheral lymphocytes from tumourbearing donors are often cytotoxic in vitro against cultured tumour cells from the same individual. This was demonstrated, for example, using a colony inhibition method, in experiments showing that lymph node cells from mice bearing primary Moloney virus-induced sarcomas reduced the colony-forming capacity of Moloney sarcoma cells when compared with the effect of lymphoid cells from normal mice or mice bearing chemicallyinduced sarcomas (Hellstrom & Hellstrom 1969) . This colony inhibition technique, or a microcytotoxicity variant of the test employing Falcon microwell plastic dishes (Hellstrom, Hellstrom, Sjogren & Warner 1971) , has been used to detect cytotoxic lymphocytes in animals bearing tumours induced by chemical carcinogens or oncogenic viruses, and tumours arising without deliberate inducement. Comparably, peripheral lymphocytes from patients with a variety of malignant lesions including melanoma, neuroblastoma, mesothelioma, and carcinomas of the breast, lung, ovary and colon, are also cytotoxic for plated cells of a similar tumour type (Hellstr6m, Hellstrom, Sjogren & Warner 1971).
These findings led to the suggestion that the serum of tumour-bearing hosts may contain factors which interfere with cell-mediated immunity, which is judged to be of prime importance in eliciting tumour rejection. This hypothesis has since been supported by the demonstration that lymphocyte cytotoxicity against cultured tumour cells could be abrogated by prior exposure of tumour cells to serum of tumour-bearing animals. In tests with transplanted hepatomas, for example, treatment of cultured hepatoma cells with lymph node cells from rats immunized to the tumour produced between 21.1 % and 37.5% inhibition compared with the colony numbers in dishes treated with lymph node cells from normal rats. If, however, tumour cells were initially exposed, for a period of 45 minutes, to serum from rats bearing the homologous tumour, lymphocyte cytotoxicity was markedly reduced (-36.6% to 12.6% inhibition of colony formation). A characteristic feature of the chemically induced hepatomas used in this work is that each tumour expresses an individually distinct tumour antigen (Baldwin et al. 1971) . In keeping with this characteristic, target hepatoma cells were only protected from lymphocyte killing by serum from a rat bearing the homologous tumour (Baldwin, Embleton & Robins 1973) .
At present, the mechanism of the blocking of lymphocyte-mediated cytotoxicity is unknown, but there is a growing body of evidence concerning the nature of the blocking factor(s) in tumourbearer serum. Several findings indicate that tumour-specific antibody may be involved. Firstly, as illustrated in rat hepatoma studies (Baldwin, Embleton & Robins 1973 ) the specificity of serum blocking is identical to that of the antibody response elicited against the tumour-associated antigens. Secondly, fractionation ofrat hepatomabearer serum by Sephadex G200 chromatography or by density gradient centrifugation (Baldwin & Robins 1972, unpublished) indicated that blocking activity separates with 7S immunoglobulins. A similar observation was reported by Hellstrom & Hellstrom (1969) , showing that the blocking factor in serum ofmice bearing Moloney sarcomas was isolated in the 7S fraction following Sephadex G200 chromatography. It was also shown that this blocking activity could be neutralized by the addition of goat anti mouse 7S immunoglobulin antisera.
Serum blocking activity is rapidly lost, however, in animals rendered tumour free by surgery, or following spontaneous regression of certain tumours, such as Moloney virus-induced sarcomas (Hellstrom & Hellstrom 1970) . For example, serum taken within three days of excision of subcutaneous grafts of transplanted hepatomas no longer blocked lymph node cell-mediated cytotoxicity, and serum collected seven or fourteen days after excision contained complementdependent cytotoxic antibody of the same specificity as the blocking activity. These observations are in agreement with studies showing that serum-blocking activity is rapidly lost following spontaneous regression of Shope papillomas (Hellstr6m et al. 1969) and similar effects have been detected in patients who have become clinically symptom free (Hellstrom, Sjogren, Warner & Hellstrom 1971 , Sjogren et al. 1972 . These observations are difficult to reconcile with the view that the serum factor abrogating cellmediated immunity is circulating antibody. This would require that the factor responsible for blocking belonged to a particular antibody class with an especially short half-life, whose production would cease immediately the tumour is excised. Furthermore, it has been demonstrated in other studies that the in vitro lymphocyteblocking activity of serum from tumour-bearing animals or patients can be neutralized by the addition of appropriate amounts of serum from tumour-free individuals (Hellstrom & Hellstrom 1970 , Bansal & Sjogren 1971 , Hellstr6m, Sjogren, Warner & Hellstrom 1971 ).
These observations are not compatible with the concept of antibody as the blocking species in the serum of tumour-bearing individuals. An alternative concept is that this effect is mediated by circulating complexes of tumour-specific antibody combined to released tumour antigen (Sjogren et al. 1971) . Loss of blocking activity following tumour excision or regression can be interpreted on the basis that both antigen and antibody components of the blocking factor are necessary for blocking activity. The antigen moiety would be derived by degradation of cellular material continuously released from the progressively growing tumour. Antigen levels would, therefore, quickly decline after tumour excision, resulting in loss of blocking activity.
The concept is supported by the finding that the blocking factor in serum from mice bearing Moloney virus-induced sarcomas can be absorbed on to viable Moloney sarcoma cells and, following elution with low pH buffer (glycine/HCl pH3), separated into high and low molecular weight components, which individually lack blocking activity. Fractionation was achieved by ultrafiltration first through a membrane retaining molecules above 100 000 molecular weight (frac-tionElOO), whichwouldincludeimmunoglobulins, and then the filtrate was passed through a second membrane, retaining molecules above 10 000 molecular weight (ElO). Tests on these fractions showed that individually they were devoid of lymphocyte-blocking activity, but this was restored when they were recombined in their original proportions. Blocking factors have also been eluted from human tumours (Sjogren et al. 1972) and again low and high molecular weight fractions individually failed to block the cytotoxic action of patients' lymphocytes, but in a 1:1 mixture of the two the blocking activity was restored. In tests where the two fractions were added separately to plated tumour cells, treatment with 'low molecular weight' followed by 'high molecular weight' fractions did not protect the tumour cells against lymphocyte cytotoxicity. If the sequence was reversed, treating tumour cells with the 'high molecular weight' fraction first, then blocking occurred. The 'high' and 'low' molecular weight fractions could therefore contain specific antibody and tumour antigen respectively, although neither has so far been definitively characterized.
Direct proof that tumour-specific antigenantibody complexes can block lymphocytemediated cytotoxicity for cultured tumour cells has been obtained in tests with a transplanted hepatoma D23 (Baldwin, Price & Robins 1972) . In previous studies, it was established that serum taken from rats fourteen days after the surgical removal of a subcutaneous tumour graft (postexcision serum) contained antibody cytotoxic for the cells of this tumour in the presence of complement (Baldwin, Embleton & Robins 1973) . This antibody was directed specifically against the tumour antigens associated with hepatoma D23, since the sera were not cytotoxic for cells of other hepatomas. Membrane biochemical studies have resulted in the isolation and partial purification of hepatoma D23 antigen in a soluble form (Baldwin & Glaves 1972 ). An extranuclear membrane fraction was prepared from homogenized hepatoma D23 tissue, and antigen solubilized by limited papain digestion. The soluble digest was purified by DEAE cellulose chromatography, fractions containing antigenic proteins being identified by absorption of specific antibody from syngeneic tumour immune serum, as assayed by membrane immunofluorescence. Mixtures of various proportions of post-excision serum (known to contain specific antibody) and solubilized tumour antigen were tested for blocking activity. No blocking of lymphocyte cytotoxicity occurred with mixtures containing a very high or very low proportion of antigen preparation. With intermediate mixtures, however, blocking activity was observed. Thus specific antigen-antibody complexes were shown to be capable of blocking lymphocyte cytotoxicity.
The role of the antigen moiety of the blocking complex in the blocking mechanism presumably involves an interaction with the sensitized lymphocyte. Direct blocking of the cytotoxicity of immune lymphocytes by admixture of tumour bearer serum might be expected under these circumstances. Such blocking has been demonstrated with transplanted hepatomas. Hepatomaimmune lymphocytes showed cytotoxic activity after prior exposure to normal rat serum (24.2-33.8 % inhibition) but this cytotoxicity was abolished by pre-exposure of the lymphocytes to the corresponding tumour bearer serum (-3.1 % to 11.9% inhibition). This effect was specific: pre-exposure of hepatoma D23 immune lymph node cells to hepatoma D30 tumour bearer serum did not effect their cytotoxicity for D23 target cells. Preliminary results have indicated that papain-solubilized hepatoma antigen preparations may also directly block lymphocyte cytotoxicity.
In parallel with these findings it has been established that immunization ofrats with tumour antigen-containing plasma membrane fractions from rat hepatoma D23 elicits poor stimulation of sensitized lymphocytes, the main response being the production of tumour specific antibody. The overall immune response to tumour membrane immunization therefore was nonprotective and moreover treated animals were refractory to subsequent immunization with irradiated hepatoma cells which in normal rats produces tumour resistance (Baldwin & Moore 1971 Traditionally tolerance or specific unresponsiveness was conceived as the abolition or diminution in parallel of all the classes of immune response to an antigen. However, unresponsiveness may selectively depress antibody production (Parish & Liew 1972) or delayed hypersensitivity (see Asherson 1967) . This underlines the possibility that unresponsiveness may sometimes be due to one type of immune response depressing another type.
The classical concept of tolerance is that antigen, e.g. in the body fluids, directly affects antigensensitive cells and deletes or inactivates them (Billingham et al. 1956 ). This concept may be called 'direct antigen-mediated unresponsiveness'. A special version of this concept is that antigen on the surface of a cell, such as a macrophage, may selectively trap, inactivate or kill antigensensitive cells (Ada & Parish 1968 ). This classical view has been modified for three reasons. Firstly, the concept that tolerance is due to the deletion or long-term inactivation of cells does not apply to systems in which unresponsiveness can be reversed by simple manipulations. Secondly, there is evidence that tolerance is sometimes a positive phenomenon, i.e. one set of cells or their products (e.g. antibody) may block the response of a second set of cells. Finally, the role of the thymus in depressing immune responses and in the induction of positive unresponsiveness in certain systems is against the general applicability of the classical view.
Short and long lasting inactivation of cells in unresponsive animals: The classical view of tolerance suggested that cells were deleted or inactivated for a long period and that recovery depended on the genesis of new antigen-sensitive cells. This view was supported by the finding that thymectomy delayed recovery from unresponsiveness to bovine serum albumin in the mouse (Taylor 1964) . However, there are several systems in which antigen-binding cells can be found in apparently unresponsive animals and in which cells from tolerant animals can be reactivated by simple procedures. For instance, unresponsiveness to E. coli lipopolysaccharide and other antigens can be ended by injecting the unresponsive cells into irradiated recipients or by incubating unresponsive cells into irradiated recipients or by incubating unresponsive cells overnight in vitro (see Sjoberg 1972) . This reversal of unresponsiveness may be due to the genesis of new antigensensitive cells but the removal of surface antibody, antigen or immune complexes seems a more likely mechanism. These unresponsive animals possess cells able to bind antigen and this indicates that not all cells able to interact with the antigen have been eliminated.
Positive unresponsiveness: An alternative concept of tolerance is that one set of cells or their products, e.g. antibody, blocks the response of a second set of cells. This has been called 'positive unresponsiveness ' (Asherson et al. 1971a) or 'infectious tolerance' Gershon & Kondo 1971) and where the detailed mechanism is known it may be further qualified as 'thymus dependent', 'antibody mediated' or 'immune complex mediated unresponsiveness'.
There are four criteria for positive unresponsiveness:
(1) Failure of normal lymphoid cells to restore immune competence to unresponsive recipients.
